2009
Phase I study combining an IGFR inhibitor (IMC-A12) and an mTOR inhibitor (temsirolimus) in patients with solid tumors or lymphoma
Naing A, LoRusso P, Mills G, Berry D, Doyle L, Rohren E, Burger A, Chen H, Busaidy N, Kurzrock R. Phase I study combining an IGFR inhibitor (IMC-A12) and an mTOR inhibitor (temsirolimus) in patients with solid tumors or lymphoma. Journal Of Clinical Oncology 2009, 27: e14535-e14535. DOI: 10.1200/jco.2009.27.15_suppl.e14535.Peer-Reviewed Original ResearchIMC-A12MTOR inhibitorsDose cohortsSolid tumorsBiologic effectsType I insulin-like growth factor receptorCommon grade 1Dose-escalation cohortsImmunosuppressive agent sirolimusLambda monoclonal antibodySolid tumor histologiesGrade 2 toxicityAdvanced solid tumorsHistory of diabetesI insulin-like growth factor receptorInsulin-like growth factor receptorCombination of temsirolimusGrowth factor receptorStable diseaseEscalation cohortsWeekly doseTumor histologyGrade 3IGFR inhibitorsTherapeutic effect
2008
554 POSTER Pharmacokinetic (PK) and pharmacodynamic (PD) results of Phase I studies of IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid malignancies
Rothenberg M, Poplin E, LoRusso P, Yu E, Schwartz J, Fox F, Mehnert J, Sandler A, Rowinsky E, Higano C. 554 POSTER Pharmacokinetic (PK) and pharmacodynamic (PD) results of Phase I studies of IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid malignancies. European Journal Of Cancer Supplements 2008, 6: 174-175. DOI: 10.1016/s1359-6349(08)72488-1.Peer-Reviewed Original Research
2007
A phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid tumors
Higano C, Yu E, Whiting S, Gordon M, LoRusso P, Fox F, Katz T, Roecker J, Schwartz J. A phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid tumors. Journal Of Clinical Oncology 2007, 25: 3505-3505. DOI: 10.1200/jco.2007.25.18_suppl.3505.Peer-Reviewed Original ResearchIMC-A12IgG1 monoclonal antibodySolid tumorsAdvanced refractory solid tumorsHuman anti-human antibodiesMedian age 56 yearsMonoclonal antibodiesNon-compartmental PK analysisGrade 2 anemiaGrade 3 hyperglycemiaHuman IgG1 monoclonal antibodyStable radiographic diseaseTreatment related toxicityInfusion-related reactionsAdvanced solid tumorsAge 56 yearsRefractory solid tumorsHuman insulinPhase I trialWeek observation periodAnti-human antibodiesDiscolored fecesECOG PSStable diseaseStudy discontinuation
2006
648 POSTER A phase I dose-escalation study of weekly IMC-A12, a fully human insulin like growth factor-I receptor (IGF-IR) IgG1 monoclonal antibody (Mab), in patients (pts) with advanced cancer
Higano C, Gordon M, LoRusso P, Fox F, Katz T, Roecker J, Rowinsky E, Youssoufian H. 648 POSTER A phase I dose-escalation study of weekly IMC-A12, a fully human insulin like growth factor-I receptor (IGF-IR) IgG1 monoclonal antibody (Mab), in patients (pts) with advanced cancer. European Journal Of Cancer Supplements 2006, 4: 195. DOI: 10.1016/s1359-6349(06)70653-x.Peer-Reviewed Original Research